Thailand’s Public Health Ministry plans to order 2 forms of antiviral oral therapy in its fight towards Covid-19. The Bangkok Post stories that the ministry desires to order supplies of the Molnupiravir antiviral capsule, as nicely as Pfizer’s new oral treatment, Paxlovid. Dr Atthasit Srisubat from the Department of Medical Services has confirmed the decision, following the recent order from PM Prayut Chan-o-cha. He says the Public Health Ministry will shortly seek Cabinet approval for the procurement of Molnupiravir, the tablet developed by Merck and Ridgeback Biotherapeutics in the US.
“If accredited, the drug is more doubtless to be delivered in late December or January next 12 months.”
Atthasit adds that talks are ongoing with Pfizer in relation to procurement of the firm’s new Covid-19 therapy, Paxlovid.
“The ministry has been in talks with the company over this drug candidate since August this yr when the results of its study were not available.”
The Bangkok Post stories that both oral remedies have proven promising leads to research, chopping the risk of hospitalisation for Covid-19 sufferers, if administered within days of symptoms developing. Atthasit says both Molnupiravir and Paxlovid work by stopping the virus from multiplying, thereby decreasing the severity of illness. Both treatments have proved effective in opposition to gentle or average signs and in high-risk patients.
“Both drugs are effective in lowering hospitalisations and preventing deaths. Molnupiravir may also be used to treat influenza, while Paxlovid is developed to specifically deal with Covid-19.”
He adds that the price of the treatments has not yet been confirmed, but there’s a risk that the price of Molnupiravir could vary depending on whether or not it’s being bought to developed or creating countries. The therapy is presently awaiting emergency use approval from the US Food and Drug Administration.
Meanwhile, Pfizer is in the means of applying for US FDA approval for Paxlovid.
For Factors on Covid-19 Insurance, CLICK HERE..